Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis

Summary

This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM. A pre-screening period using brain MRI for patients diagnosed with advanced non-squamous NSCLC EGFR/ALK wild type and ECOG PS 0-1 will be crucial to identify patients with asyntomatic BM. Forty patients will be recruited.

Timeline

Start

2018-07-07

Primary completion

2022-03-31

Completion

2022-09-15

Publications

• Nadal E, Rodriguez-Abreu D, Simo M, Massuti B, Juan O, Huidobro G, Lopez R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilarino N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). J Clin Oncol. 2023 Oct 1;41(28):4478-4485. doi: 10.1200/JCO.22.02561. Epub 2023 Aug 21.

Drugs

Indications